Two Organizations. One Mission.
Hope in Action is powered by a partnership between ASF and FAST — the two leading Angelman syndrome organizations in the world — united to advocate for the families and individuals who need it most.
Who We Are
The two leading Patient Advocacy Organizations around the global have joined forces in their efforts to advocate together for Angelman syndrome.
The mission of the Angelman Syndrome Foundation (ASF) is to advance the awareness and treatment of Angelman syndrome through education and information, research, and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a transformational therapeutic.
The Foundation for Angelman Syndrome Therapeutics (FAST) shares a resolute goal: to cure Angelman syndrome. As the world’s largest non-governmental funder of Angelman syndrome research, they focus on expediting safe and effective treatments into current medical practice. They work tirelessly to transform the future for individuals affected by Angelman syndrome.
Our Commitment
The Angelman Syndrome Foundation (ASF) and the Foundation for Angelman Syndrome Therapeutics (FAST) are united and committed to making a significant impact in the Angelman syndrome community through grassroots
advocacy. This commitment is what led us to jointly launch Hope in Action: Progress through advocacy. “Hope in Action” is a call to action – to recruit a grassroots network of Angelman syndrome families and friends to foster relationships with members of state, local, and federal governments to advocate for policies that have the potential to positively impact the lives of our families.
Together, ASF and FAST combine their strengths and expertise, creating a powerful force that drives progress, offers support, and seeks transformative treatments for Angelman syndrome. Our collaborative efforts epitomize our shared dedication to making a lasting difference in the lives of those we serve.
Our Angelman Syndrome Advocacy Priorities:
- Increase the federal focus and research investment in Angelman syndrome.
- Support legislation to improve the quality of life for people with AS and their families.
- Ensure that regulatory & public policies reflect the needs of the AS community.
- Advocate for FDA flexibility and appropriate speed in review of potential therapies.
- Ensuring family experiences and preferences are integrated into therapy development and delivery, from study design through health plan access.
- Support legislation and policy at the state and federal level aimed at supporting caregivers.
Together, ASF and FAST combine their strengths and expertise, creating a powerful force that drives progress, offers support, and seeks transformative treatments for Angelman syndrome. Our collaborative efforts epitomize our shared dedication to making a lasting difference in the lives of those we serve.